Top Challenges Facing The Recombinant DNA Technology Industry | Healthcare Industry Spotlight

The "Recombinant DNA Technology" is a process that manipulates and alters the DNA sequences, resulting in a genetically modified organism and product. These genetically modified products or organisms have superior or specific ability such as resistance to certain chemicals, high productivity, and survival abilities in harsh conditions (GM crops).

The recombinant DNA technology has a practical application of biotechnology in the fields of applied immunology, genomics, diagnostic tools, and development of pharmaceutical therapeutics. There are numerous biological methods used to create a recombinant DNA. The treatment was developed for leukemia disorder, in conjugation between the Novartis Corp and the University of Pennsylvania.

Factors such as the commercial success of the recombinant DNA technology in the biopharmaceutical industry, the increasing adoption of genetically modified crops and biopesticides, and the increasing burden of chronic diseases are driving the growth of the market. Moreover, the increasing need to improve the recombinant protein production capacity and the presence of robust biopharmaceuticals pipeline are increasing the demand for effective therapeutics for disease treatment.

Presently, the genetic testing market is majorly spread in Western Europe and North American. There are vast opportunities for the companies and service providers to make the tests affordable and enter the untapped regions of the world with a great scope of expanding. The global recombinant DNA technology market is expected to grow at a CAGR of approximately 6.9% during the forecast period, 2017–2023.

Get Premium Sample Copy of Recombinant DNA Technology Market @ https://www.marketresearchfuture.com/sample_request/5845

Global Recombinant DNA Technology Market — Regional Analysis

The global recombinant DNA technology market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas region holds the largest market share of the global recombinant DNA technology market due to the presence of effective regulations pertaining to the approval of recombinant therapeutics and other Genetically Modified (GM) products. F. Hoffmann-La Roche Ltd, Amgen Inc., Novartis AG, Monsanto Company, Eli Lilly and Company, and Biogen Inc. are some of the major companies operating in this space that are responsible for the growth of the Americas recombinant DNA technology market.

Furthermore, there is an increasing need to improve the recombinant proteins production capacity by several folds in Europe. The increase in demand for effective therapeutics for the treatment of diseases and technological advancements in this sector are anticipated to drive the growth of the European recombinant DNA technology market.

Asia Pacific is expected to emerge as the fastest growing regional market for the global recombinant DNA technology market. The increasing awareness about the growing genetic diseases and disorders, developing healthcare infrastructure, increasing spending on healthcare, increasing government initiatives to improve public health, and advances in medical fields are driving the market growth.
The Middle East and Africa is expected to experience a limited growth due to less demand for genetic testing. The Middle East is growing significantly as compared to the African recombinant DNA technology market owing to the increase in aging population, innovations in genetic testing, and increase in the number of chronic disease cases.

Intended Audience

• Recombinant DNA Technology Test Kit Suppliers
• Recombinant DNA Technology Test Kit Manufacturers
• Research and Development (R&D) Companies
• Medical Research Laboratories
• Academic Medical Institutes and Universities

Leading Players in the Recombinant DNA Technology Market:

F. Hoffmann-La Roche Ltd (Switzerland), Profacgen (U.S.), Amgen Inc. (U.S.), Novartis AG (Switzerland), Genscript Biotech (U.S.), Pfizer Inc. (U.S.), Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Sanofi S.A. (France), Merck & Co., Inc. (U.S.), Biogen Inc. (U.S.), Biocon Limited (India), GlaxoSmithKline plc (UK), New England Biolabs (U.S.), Cibus (U.S.), Monsanto Company (U.S.), Horizon Discovery Group PLC (U.S.), Boehringer Ingelheim (Germany), and others.

Market Segmentation:

The global recombinant DNA technology market is segmented on the basis of product, component, application, and end-user.

On the basis of product, the global recombinant DNA technology market is segmented into medical, non-medical, and others. The medical segment is divided into therapeutic agent, human protein, and vaccines. The non-medical segment is divided into biotech crops, specialty chemicals, and others.

On the basis of component, the global recombinant DNA technology market is segmented into expression system, cloning vector, and others. The expression system segment is divided into mammalian, bacteria, yeast, baculovirus/insect, and others. The cloning vector segment is divided into plasmid, phage, cosmid, Bacterial Artificial Chromosome (BAC), Yeast Artificial Chromosome (YAC), and Human Artificial Chromosome (HAC).
On the basis of application, the global recombinant DNA technology market is segmented into food and agriculture, health and disease, environment, and others.

On the basis of end-user, the global recombinant DNA technology market is segmented into biotechnology companies, academic and government research institutes, pharmaceuticals, and others.

Avail Premium Discount @ https://www.marketresearchfuture.com/check-discount/5845

TOC of Recombinant DNA Technology Market Research Report — Global Forecast to 2023

1. Report Prologue

2. Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market Structure
2.4. Market Segmentation

3. Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model

4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Threats
4.5 Macroeconomic Indicators

TOC CONTINUED…

Ask any Queries to Experts about Niche Segments, Requires Regional Data and Top Players @ https://www.marketresearchfuture.com/enquiry/5845

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:
Market Research Future
Office №528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune — 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.